Neupharma announces the positive conclusion of the phase 1 study, conducted at the “Azienda Ospedaliera Universitaria Integrata” of Verona, with the formulation of inhaled teicoplanin in CF patients.
The German Quality and Finance Institute published the results of the research entitled "Champions of Growth": the aim was rewarding the 400 companies whose turnover increased most in the three-year period 2016-2019.
The Food and Drug Administration has granted the Pediatric Orphan Drug Designation to the inhaled formulation of Teicoplanin for patients with Cystic Fibrosis.
Neupharma, one of the finalists for the category "Companies - Health & Pharma" from “Le Fonti Awards”, wins the title "Excellence of the Year - Innovation & Leadership - Medical Devices for Cystic Fibrosis"
The European Commission has granted the designation of orphan drug to Teicoplanin in inhalation formula for cystic fibrosis, a formula developed by Neupharma in collaboration with the non-profit company Rare Partners.
